Insider decken sich bereits ein, denn die Zulassung eines Potenzsprays steht unmittelbar bevor. Experten schätzen das Marktvolumen auf jährlich 500 Millionen USD.
Für Interessierte:
Aus dem Yahoo-Message-Board:
Nastechs (NSTK) new drug is against "male erectile dysfunction" = impotence..
SG Cowan predicts of this substance which is in the new drug yrl. generating revenues of 500 Mio USD ( look Viagra generating about 850 mio) !
Nstk should grab a good share of this revenues !
The APPROVAL WILL BE ANNOUNCED SOON !!!
Kurzbeschreibung:
Nastech Pharmaceutical Company Inc. is engaged in the research, development, manufacturing and commercialization of nasally administered forms of prescription and over-the-counter pharmaceuticals that are currently delivered in oral, injectable or other dosage forms with particular emphasis on treating conditions mediated by the central nervous system. The Company's first commercially available pharmaceutical is prescription pain reliever marketed as Stadol NS by Bristol-Myers Squibb Company. Stadol NS is the only transnasal opioid analgesic therapy marketed for the treatment of moderate to severe pain and the acute pain of migraine. Similarly, Nascobal (Cyanocobalamin, USP) Gel for Intranasal Administration, the Company's nasal Vitamin B-12 product, provides both therapeutic and patient benefits over injectable therapy for chronic Vitamin B-12 deficiency anemia.
Die Aktie ist bei einem aktuellen Kurs von 3,5 Euro im Vergleich zur Konkurrenz massiv unterbewertet!
Price/Book (mrq) 1.08
Price/Earnings N/A
Price/Sales (ttm) 3.66
Für Interessierte:
Aus dem Yahoo-Message-Board:
Nastechs (NSTK) new drug is against "male erectile dysfunction" = impotence..
SG Cowan predicts of this substance which is in the new drug yrl. generating revenues of 500 Mio USD ( look Viagra generating about 850 mio) !
Nstk should grab a good share of this revenues !
The APPROVAL WILL BE ANNOUNCED SOON !!!
Kurzbeschreibung:
Nastech Pharmaceutical Company Inc. is engaged in the research, development, manufacturing and commercialization of nasally administered forms of prescription and over-the-counter pharmaceuticals that are currently delivered in oral, injectable or other dosage forms with particular emphasis on treating conditions mediated by the central nervous system. The Company's first commercially available pharmaceutical is prescription pain reliever marketed as Stadol NS by Bristol-Myers Squibb Company. Stadol NS is the only transnasal opioid analgesic therapy marketed for the treatment of moderate to severe pain and the acute pain of migraine. Similarly, Nascobal (Cyanocobalamin, USP) Gel for Intranasal Administration, the Company's nasal Vitamin B-12 product, provides both therapeutic and patient benefits over injectable therapy for chronic Vitamin B-12 deficiency anemia.
Die Aktie ist bei einem aktuellen Kurs von 3,5 Euro im Vergleich zur Konkurrenz massiv unterbewertet!
Price/Book (mrq) 1.08
Price/Earnings N/A
Price/Sales (ttm) 3.66
